Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame

被引:25
|
作者
Thompson, Kimberly M. [1 ]
Kalkowska, Dominika A. [1 ]
机构
[1] Kid Risk Inc, 7512 Dr Phillips Blvd 50-523, Orlando, FL 32819 USA
关键词
dynamic modeling; eradication; oral poliovirus vaccine; polio; POPULATION IMMUNITY; PARALYTIC POLIOMYELITIS; GLOBAL ERADICATION; COST-EFFECTIVENESS; VACCINE CESSATION; RISK; CIRCULATION; STRATEGIES; MANAGEMENT; OUTBREAKS;
D O I
10.1111/risa.13484
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The Global Polio Eradication Initiative (GPEI) partners engaged modelers during the past nearly 20 years to support strategy and policy discussions and decisions, and to provide estimates of the risks, costs, and benefits of different options for managing the polio endgame. Limited efforts to date provided insights related to the validation of the models used for GPEI strategy and policy decisions. However, modeling results only influenced decisions in some cases, with other factors carrying more weight in many key decisions. In addition, the results from multiple modeling groups do not always agree, which supports selection of some strategies and/or policies counter to the recommendations from some modelers but not others. This analysis reflects on our modeling, and summarizes our premises and recommendations, the outcomes of these recommendations, and the implications of key limitations of models with respect to polio endgame strategy. We briefly review the current state of the GPEI given epidemiological experience as of early 2020, which includes failure of the GPEI to deliver on the objectives of its 2013-2018 strategic plan despite full financial support. Looking ahead, we provide context for why the GPEI strategy of global oral poliovirus vaccine (OPV) cessation to end all cases of poliomyelitis looks infeasible given the current state of the GPEI and the failure to successfully stop all transmission of serotype 2 live polioviruses within four years of the April-May 2016 coordinated cessation of serotype 2 OPV use in routine immunization.
引用
收藏
页码:229 / 247
页数:19
相关论文
共 50 条
  • [41] Experiences and Lessons From Polio Eradication Applied to Immunization in 10 Focus Countries of the Polio Endgame Strategic Plan
    van den Ent, Maya M. V. X.
    Mallya, Apoorva
    Sandhu, Hardeep
    Anya, Blanche-Philomene
    Yusuf, Nasir
    Ntakibirora, Marcelline
    Hasman, Andreas
    Fahmy, Kamal
    Agbor, John
    Corkum, Melissa
    Sumaili, Kyandindi
    Siddique, Anisur Rahman
    Bammeke, Jane
    Braka, Fiona
    Andriamihantanirina, Rija
    Ziao, Antoine-Marie C.
    Djumo, Clement
    Yapi, Moise Desire
    Sosler, Stephen
    Eggers, Rudolf
    JOURNAL OF INFECTIOUS DISEASES, 2017, 216 : S250 - S259
  • [42] Survey of poliovirus antibodies during the final stage of polio eradication in Egypt
    El-Sayed, Nasr
    Al-Jorf, Samir
    Hennessey, Karen A.
    Salama, Maha
    Watkins, Margaret A.
    Abdelwahab, Jalaa A.
    Pallansch, Mark A.
    Gary, Howard
    Wahdan, Mohamed Helmy
    Sutter, Roland W.
    VACCINE, 2007, 25 (27) : 5062 - 5070
  • [43] The resurgence of wild poliovirus in Pakistan and Afghanistan: A new setback for polio eradication
    Rana, Muhammad Suleman
    Asghar, Rana Jawad
    Usman, Muhammad
    Ikram, Aamer
    Salman, Muhammad
    Umair, Massab
    Zaidi, Syed Sohail Zahoor
    Anas, Muhammad
    Ullah, Nadeem
    JOURNAL OF INFECTION, 2022, 85 (03) : 344 - 345
  • [44] Will India need inactivated poliovirus vaccine (IPV) to complete polio eradication?
    John, TJ
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2005, 122 (05) : 365 - 367
  • [45] Coverage estimates and patterns of inactivated poliovirus vaccine (IPV) use prior to and during the polio eradication endgame, Jinan City, China, 2010-2015
    Chang, Caiyun
    Zhang, Ji
    Zhou, Jingwen
    Cao, Ruoming
    Song, Kaijun
    Liu, Chong
    Zhang, Xianhui
    Geng, Xingyi
    Liu, Xiaoxue
    Li, Chuanbin
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2016, 12 (11) : 2749 - 2752
  • [46] Polio eradication: interrupting transmission, towards a polio-free world
    Heymann, David L.
    Sutter, Roland W.
    Aylward, R. Bruce
    FUTURE VIROLOGY, 2006, 1 (02) : 181 - 188
  • [47] Impact of Maternal Antibody on the Immunogenicity of Inactivated Polio Vaccine in Infants Immunized With Bivalent Oral Polio Vaccine: Implications for the Polio Eradication Endgame
    Gaensbauer, James T.
    Gast, Chris
    Bandyopadhyay, Ananda S.
    O'Ryan, Miguel
    Saez-Llorens, Xavier
    Rivera, Luis
    Lopez-Medina, Eduardo
    Melgar, Mario
    Weldon, William C.
    Oberste, M. Steven
    Ruttimann, Ricardo
    Clemens, Ralf
    Asturias, Edwin J.
    CLINICAL INFECTIOUS DISEASES, 2018, 67 : S57 - S65
  • [48] Health economic analysis of vaccine options for the polio eradication endgame: 2022-2036
    Thompson, Kimberly M.
    Kalkowska, Dominika A.
    Badizadegan, Kamran
    EXPERT REVIEW OF VACCINES, 2022, 21 (11) : 1667 - 1674
  • [49] Poliovirus vaccination during the endgame: insights from integrated modeling
    Tebbens, Radboud J. Duintjer
    Thompson, Kimberly M.
    EXPERT REVIEW OF VACCINES, 2017, 16 (06) : 577 - 586
  • [50] Circulating vaccine-derived poliovirus: a menace to the end game of polio eradication
    Ming, Long Chiau
    Hussain, Zahid
    Yeoh, Siang Fei
    Koh, David
    Lee, Kah Seng
    GLOBALIZATION AND HEALTH, 2020, 16 (01)